Restoring Dystrophin via Exon Skipping Strategies AOC 1044 – Mark Stahl, MD (Avidity Biosciences) BMN 351 – Dave Jacoby MD, PhD (BioMarin Pharmaceutical Inc.) DYNE-251 – Ash Dugar, PhD, MBA (Dyne Therapeutics) ED051 – Michelle Mellion, MD (PepGen, Inc.) ENTR-601-44 – Nerissa Kreher, MD, MBA (Entrada Therapeutics) SRP-5051 – Teji Singh, MD (Sarepta Therapeutics) WVE-N531 – Mike Panzara, MD, MPH (Wave Life Sciences) 2022 PPMD Annual Conference,Conferences & Meetings 2 years ago You may also like 13:19 PTC Therapeutics 4 years ago Approved Therapies,Conferences & Meetings 15:43 Sarepta Therapeutics 4 years ago Approved Therapies,Conferences & Meetings 7:48 What is a Post Market Study? 4 years ago Approved Therapies,Conferences & Meetings 35:48 DPT Meeting: Welcome & Introduction 5 years ago 2019 Duchenne Platform Trial Stakeholder Meeting,Conferences & Meetings 38:43 DPT Meeting: FDA Opening Remarks 5 years ago 2019 Duchenne Platform Trial Stakeholder Meeting,Conferences & Meetings 23:02 DPT Meeting: DPT Protocol in Practice 5 years ago 2019 Duchenne Platform Trial Stakeholder Meeting,Conferences & Meetings 43:44 DPT Meeting: Overview of DPT Proposed Protocol 5 years ago 2019 Duchenne Platform Trial Stakeholder Meeting,Conferences & Meetings 49:36 DPT Meeting: Panel 1 – Protocol Objectives & Eligibility 5 years ago 2019 Duchenne Platform Trial Stakeholder Meeting,Conferences & Meetings «1…202122232425»Page 22 of 25
by: Parent Project Muscular Dystrophy
